On June 6, 2024, SeaStar Medical Holding Corporation, a Delaware-incorporated company listed on the Nasdaq Stock Market under the symbol ICU, reported significant financial transactions with an institutional investor known as Investor D. The company redeemed $0.7 million of the remaining outstanding convertible notes that were originally issued on December 11, 2023, along with accrued interest and make-whole amounts. The redemption was executed at 200% of the conversion amount as per the terms agreed upon. Concurrently, Investor D converted approximately $0.6 million of unpaid principal and $0.7 million of unpaid interest and make-whole amounts into 2,321,429 shares of common stock, which, due to a 25-for-1 reverse stock split effective from June 7, 2024, equates to 92,858 post-split shares. Following these transactions, there are no remaining outstanding Investor D convertible notes. However, Investor D retains warrants to purchase around 3,158,086 shares of SeaStar Medical's stock at a weighted-average exercise price of $0.55, which adjusts to $13.75 post-reverse split. The company's CEO, Eric Schlorff, signed off on the report.

On June 6, 2024, SeaStar Medical Holding Corporation, a Delaware-incorporated company listed on the Nasdaq Stock Market under the symbol ICU, reported significant financial transactions with an institutional investor known as Investor D. The company redeemed $0.7 million of the remaining outstanding convertible notes that were originally issued on December 11, 2023, along with accrued interest and make-whole amounts. The redemption was executed at 200% of the conversion amount as per the terms agreed upon. Concurrently, Investor D converted approximately $0.6 million of unpaid principal and $0.7 million of unpaid interest and make-whole amounts into 2,321,429 shares of common stock, which, due to a 25-for-1 reverse stock split effective from June 7, 2024, equates to 92,858 post-split shares. Following these transactions, there are no remaining outstanding Investor D convertible notes. However, Investor D retains warrants to purchase around 3,158,086 shares of SeaStar Medical's stock at a weighted-average exercise price of $0.55, which adjusts to $13.75 post-reverse split. The company's CEO, Eric Schlorff, signed off on the report.